At this point I'd be just fine with them abandoning the combo therapy BLA altogether and file a monotherapy phase 3 protocol instead. With monotherapy FDA approved it would reduce combo therapy sales to next to nothing anyways. Nobody's going to use leronlimab in combo with HAART and it's side effects when they can use leronlimab alone.